Altered vasculature and the resultant chaotic tumor blood flow lead to the appearance in fast‐growing tumors of regions with gradients of oxygen tension and acute hypoxia (less than 1.4 % oxygen).1 Due to its roles in tumorigenesis and resistance to therapy, hypoxia represents a problem in cancer therapy.1, 2 Insufficient delivery of therapeutic agents to the hypoxic regions in solid tumors is recognized as one of the causes of resistance to therapy.1, 3 This led to the development of hypoxia imaging agents,4 and the use of hypoxia‐activated anticancer prodrugs.2a Here we show the first example of the hypoxia‐induced siRNA uptake and silencing using a nanocarrier consisting of polyethyleneglycol 2000, azobenzene, polyethyleneimine (PEI)(1.8 kDa), and 1,2‐dioleyl‐sn‐glycero‐3‐phosphoethanolamine (DOPE) units (the nanocarrier is referred to as PAPD), where azobenzene imparts hypoxia sensitivity and specificity.4a We report hypoxia‐activated green fluorescent protein (GFP) silencing in vitro and its downregulation in GFP‐expressing tumors after intravenous administration. The proposed nanoformulation represents a novel tumor‐environment‐responsive modality for cancer targeting and siRNA delivery.
Altered vasculature and the resultant chaotic tumor blood flow lead to the appearance in fast-growing tumors of regions with gradients of oxygen tension and acute hypoxia (less than 1.4 % oxygen). [1] Due to its roles in tumorigenesis and resistance to therapy, hypoxia represents a problem in cancer therapy. [1, 2] Insufficient delivery of therapeutic agents to the hypoxic regions in solid tumors is recognized as one of the causes of resistance to therapy. [1,3] This led to the development of hypoxia imaging agents, [4] and the use of hypoxia-activated anticancer prodrugs. [2a] Here we show the first example of the hypoxia-induced siRNA uptake and silencing using a nanocarrier consisting of polyethyleneglycol 2000, azobenzene, polyethyleneimine (PEI)(1.8 kDa), and 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE) units (the nanocarrier is referred to as PAPD), where azobenzene imparts hypoxia sensitivity and specificity. [4a] We report hypoxia-activated green fluorescent protein (GFP) silencing in vitro and its downregulation in GFP-expressing tumors after intravenous administration. The proposed nanoformulation represents a novel tumor-environment-responsive modality for cancer targeting and siRNA delivery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.